MedTrace Logo

Phase II Randomized Study on Locally Advanced NSCLC Escalated Dose on Individual Basis Treatment With Radiochemotherapy

NCT01664663 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2014-12-09

No results posted yet for this study

Summary

The purpose of this study is to examine the valu of individually dose escalated radiotherapy compared with a standard dose of radiotherapy combined with standard concomitant chemotherapy for patients with locally advanced non small cell lung cancer (stage III) with good performance status.

Conditions

  • Non Small Cell Lung Cancer
  • Locally Advanced Disease

Interventions

RADIATION

Standard radiochemotherapy to 68 Gy

RADIATION

Dose escalated radiochemotherapy up to 84 Gy

Sponsors & Collaborators

  • Ass. Prof. Jan Nyman

    lead NETWORK

Principal Investigators

  • Jan Nyman, Ass. prof · Swedish Lung Cancer Study Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2013-11-30
Completion
2015-10-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01664663 on ClinicalTrials.gov